Agile Therapeutics (NASDAQ:AGRX) has been assigned a $3.00 target price by equities research analysts at Maxim Group in a report issued on Monday, TipRanks reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Maxim Group’s price target points to a potential upside of 125.56% from the stock’s previous close.
AGRX has been the subject of several other reports. ValuEngine raised Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 11th. Janney Montgomery Scott began coverage on Agile Therapeutics in a research report on Friday, April 12th. They set a “buy” rating and a $4.00 target price for the company. Finally, Oppenheimer began coverage on Agile Therapeutics in a research report on Thursday, June 6th. They set an “outperform” rating and a $5.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $4.00.
Shares of NASDAQ:AGRX opened at $1.33 on Monday. The firm has a market cap of $56.86 million, a P/E ratio of -2.29 and a beta of 0.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.91 and a quick ratio of 8.91. Agile Therapeutics has a 12-month low of $0.23 and a 12-month high of $1.70.
In other Agile Therapeutics news, Director Abhijeet J. Lele purchased 20,000 shares of the firm’s stock in a transaction on Friday, March 29th. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the director now owns 37,949 shares in the company, valued at approximately $58,441.46. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Alfred Altomari purchased 25,000 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were acquired at an average price of $1.54 per share, with a total value of $38,500.00. Following the completion of the acquisition, the chief executive officer now owns 238,568 shares in the company, valued at approximately $367,394.72. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 65,000 shares of company stock valued at $94,700. Company insiders own 8.50% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC raised its holdings in Agile Therapeutics by 260.7% during the 4th quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 226,255 shares during the period. BlackRock Inc. raised its holdings in Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after acquiring an additional 18,038 shares during the period. Geode Capital Management LLC raised its holdings in Agile Therapeutics by 24.0% during the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 44,639 shares during the period. Advisor Group Inc. raised its holdings in Agile Therapeutics by 716.7% during the 1st quarter. Advisor Group Inc. now owns 147,000 shares of the specialty pharmaceutical company’s stock valued at $222,000 after acquiring an additional 129,000 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Agile Therapeutics by 10.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,133,777 shares of the specialty pharmaceutical company’s stock valued at $3,222,000 after purchasing an additional 193,100 shares in the last quarter. Hedge funds and other institutional investors own 42.38% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Featured Article: Percentage Decliners
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.